MedTrace Logo

Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease

NCT03467620 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2020-03-25

No results posted yet for this study

Summary

To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomized, placebo-controlled trial assessing the efficacy and safety of oral cannabinoids as an adjunct therapy in patients with Crohn's disease.

Conditions

  • Crohn Disease
  • Inflammatory Bowel Diseases
  • Cannabis

Interventions

DRUG

Cannabidiol

Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks

DRUG

Placebo oral capsule

Administration of one oral placebo capsule daily for a duration of 12 weeks

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2019-07-31
Completion
2019-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467620 on ClinicalTrials.gov